ATRA · Atara Biotherapeutics, Inc. · Investor Relations
$9.25
-0.15 (-1.60%)
At close · Oct 6
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 12, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Our existing cash, cash equivalents and short-term investments as of June 30, 2026 will not be sufficient to fund our planned operations for at least the next twelve months from the date of issuance of these financial statements. These conditions raise substantial doubt about our ability to continue as a going concern for at least 12 months after the issuance of the accompanying condensed consolidated financial statements.”View the 10-Q filed Aug 12, 2026
Market Cap
$82.31M
Shares
10.04M
Volume · Oct 5
39.32K
Avg daily vol (3M)
57.61K
Press releases and events scraped from the company’s investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.
Past events
| Date | Event | Type |
|---|---|---|
| 2026-06-09 | Annual Meeting of Stockholders | Shareholder meeting |
Source: https://investors.atarabio.com/